Almac Clinical Technologies, part of the Almac Group, has entered a collaboration with Exostar to provide Single Sign-On (SSO) and Federated-Authentication access to eClinical applications used to support clinical trials, including Interactive Response Technology (IRT).

Under the collaboration, Almac aims to simplify credential management for both clinical sites and trial sponsors to help streamline clinical trial workflows. The SSO functionality eliminates the need for site personnel and patients to maintain multiple credentials.  When combined with credential de-provisioning, the solution aims to enhance the controls and security surrounding trial-sponsor intellectual property. The user-authentication functionality extends to other federated partners of Exostar, including TransCelerate, Merck and AstraZeneca, further augmenting the value of the platform.

“The clinical trials process is dynamic and complex.  With IXRS 3, Almac expedites drug discovery by bringing constituents, materials, and data together so the right people have access to the right information and supplies at the right time,” said Kenny Kong, Exostar’s director of Life Sciences and Health IT.  “By federating to the Exostar platform, Almac is furthering the value of their solution by enabling SSO for their clinical application, which eases the access burden on study sponsors, improves the site user experience, and raises the level of security.”

Charlie Morris, vice president of New Products & Services, Almac Clinical Technologies said, “Protecting sensitive data and securely conducting clinical trial operations are critical functions, yet can prove immensely challenging for sponsors. Exostar’s cloud-based platform provides a perfect solution to enable our clients to overcome these challenges.  We’re excited about Exostar’s dedication to streamlining identity management in the highly-regulated industry we work in, and we firmly believe that combining best-in-class technology solutions like IXRS 3 with Exostar’s identity and access management platform for life sciences will inherently unlock new value and reduce burden for the biopharmaceutical clients we serve.